FOLD - Amicus Looks To Push Gene Therapy Pipeline After Latest Expanded Agreement

Amicus Therapeutics (FOLD) is best known for its Fabry disease drug Galafold, which has already been approved by the FDA. However, in 2018, it made a huge change when it generated an agreement with the University of Pennsylvania to generate gene therapy treatments for a host of rare diseases. This push was initiated in 2018 but has now been lately expanded to include other target indications like lysosomal storage disorders and other types of rare diseases. I believe the shift to gene therapy was a smart move by the biotech, especially since there

Read more ...